SEC Form 4 · accession 0000950103-16-014334
Anacor Pharmaceuticals, Inc. · ANAC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Graeme Bell
Officer — Executive VP and CFO
Period of report
Jun 24, 2016
Accepted (ET)
Jun 24, 2016 · 2:44 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001411158
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jun 24, 2016 | D | 10,488 | $99.25 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Performance Restricted Stock UnitsF1 | — | Jun 24, 2016 | D | 8,008 | D | — | — | Common Stock | 8,008 | 0 | D |
| Performance Restricted Stock UnitsF1 | — | Jun 24, 2016 | D | 4,004 | D | — | — | Common Stock | 4,004 | 0 | D |
| Performance Restricted Stock UnitsF1 | — | Jun 24, 2016 | D | 5,000 | D | — | — | Common Stock | 5,000 | 0 | D |
| Stock Option (right to buy)F1 | $69.34 | Jun 24, 2016 | D | 28,793 | D | — | — | Common Stock | 28,793 | 0 | D |
| Stock Option (right to buy)F1 | $78.91 | Jun 24, 2016 | D | 25,299 | D | — | — | Common Stock | 25,299 | 0 | D |
Explanation of responses
- F1As of the effective time of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 14, 2016 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Quattro Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent, pursuant to the terms of the Merger Agreement, (i) each share of the Issuer's Common Stock held by the reporting person was disposed of in exchange for the merger consideration of $99.25 per share, (ii) each award of restricted stock units (including performance restricted stock units) and stock options became fully vested and (iii) each award of restricted stock units (including performance restricted stock units) and stock options was cancelled in exchange for the right to receive a cash payment per share in an amount equal to $99.25 less, in the case of stock options, the applicable exercise price.
- F2Includes shares acquired pursuant to the Issuer's ESPP since the reporting person's last Form 4.